Viking Therapeutics (VKTX) Rating Lowered to Buy at BidaskClub

Viking Therapeutics (NASDAQ:VKTX) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.

A number of other research analysts have also issued reports on the company. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Roth Capital initiated coverage on Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.00.

Viking Therapeutics (VKTX) opened at $6.17 on Thursday. The stock has a market capitalization of $286.53, a PE ratio of -7.35 and a beta of 2.26. Viking Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $7.15.

A number of large investors have recently added to or reduced their stakes in VKTX. Citadel Advisors LLC acquired a new position in shares of Viking Therapeutics in the 3rd quarter valued at $108,000. Creative Planning boosted its position in shares of Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 60,000 shares during the period. Cornerstone Capital Inc. acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at $352,000. GRT Capital Partners L.L.C. boosted its position in shares of Viking Therapeutics by 187.8% in the 4th quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 61,978 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at $124,000. 5.05% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/15/viking-therapeutics-vktx-rating-lowered-to-buy-at-bidaskclub.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply